Sign in
ZNTL Stock Price, Chart, Stats & News
Zentalis Pharmaceuticals, Inc.
Save
Zentalis Pharmaceuticals, Inc. (ZNTL) does not currently pay a dividend.
192.20M
Market cap
–
Current P/E
–
Forward P/E
ZNTL chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.32% |
ROA | -47.43% |
ROE | -52.77% |
D/E | 0.17x |
Interest coverage ratio | – |
ZNTL valuation
P/E | – |
P/S | – |
P/B | 0.70x |
P/CF | -1.20x |
P/FCF | -1.19x |
P/OCF | -1.20x |
PEG | -0.13x |
EV multiple | -1.10x |
About
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D.
Similar securities
Based on sector and market capitalization
Report issue